Comparisons of the Impact of Monotherapy With Mirabegron or Tolterodine Versus Combined Treatment With Mirabegron and Tolterodine on Autonomic Function and Bladder Blow Flow in Women With Overactive Bladder Syndrome: a Randomized Controlled Study
Female Patients With Overactive Bladder Syndrome
About this trial
This is an interventional treatment trial for Female Patients With Overactive Bladder Syndrome
Eligibility Criteria
Inclusion Criteria: >20 years old . female patients with overactive bladder syndrome Exclusion Criteria: Cases of hypersensitivity to mirabegron or tolterodine. Betanley is contraindicated in the following patients: uncontrolled severe hypertension. Dexotol is contraindicated in the following patients: known urethral diverticulum, known bladder malignancy, patients with urinary retention and gastric retention, patients with uncontrolled narrow-angle glaucoma, patients with renal dialysis, severe renal dysfunction (ie Inulin clearance rate (GFR<30 ml/min) or liver dysfunction (i.e. liver cirrhosis), use strong CYP3A4 inhibitors such as ketoconazole. Patients with myasthenia gravis. The patient is taking drugs that interact with tolterodine or mirabegron.
Sites / Locations
- Department of Obstetrics and Gynecology, Far Eastern Memorial HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Active Comparator
Experimental
mirabegron
tolterodine
combined therapy
mirabegron 25 mg
tolterodine 4 mg
tolterodine 4 mg & mirabegron 25 mg